The Need for Axillary Dissection in Patients with Positive Axillary Sentinel Lymph Nodes
- First Online:
- 285 Downloads
The need for completion axillary dissection after a positive sentinel node biopsy continues to be challenged. In the 2 years since we last reviewed this subject, a number of authors have shared their experiences about micrometastatic disease and isolated tumor cells, opining both for and against axillary treatment. Data from the ACOSOG Z0011 trial and other small studies do not appear to support the use of completion axillary dissection even for macro-metastatic disease in patients with clinically node-negative (N0) disease. While existing guidelines still recommend axillary dissection for patients with clinically positive nodes, even when conversion to clinically negative disease following neoadjuvant chemotherapy has occurred, this concept is being questioned in ACOSOG Z1071 and in several other recent small trials. The surgical approach to the treatment of breast cancer continues to move away from the traditional Halstedian concept.
KeywordsAxillary dissection Sentinel lymph node Micrometastases Micrometastasis Isolated tumor cells Completion axillary dissection Neoadjuvant Chemotherapy
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Krag DN, Stewart JA, Julian TB, et al.: Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomized phase III trial. Lancet Oncol 2007, 8:881–888.CrossRefPubMedGoogle Scholar
- 6.•• Giuliano AE, McCall LM, Beitsch PD, et al.: ACOSOG Z0011: a randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. J Clin Oncol 2010, 28(Suppl):abstr CRA506. This study reports on a large phase 3 trial to date revealing no benefit of axillary node dissection for patients with clinically node negative but pathologically positive sentinel nodes.Google Scholar
- 13.• Reed J, Rosman M, Verbanac KM, et al.: Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg 2009, 208:333–340. The rate of distant recurrence is reported at 4.9 years and reveals increased recurrence risk in patients with isolated tumor cells, micrometastases, and macrometastases in sentinel nodes.CrossRefPubMedGoogle Scholar
- 14.• Truong PT, Lesperance M, Li KH, et al.: Micrometastatic node-positive breast cancer: Long-term outcomes and identification of high-risk subsets in a large population-based series. Ann Surg Oncol 2010, 17:2138–2146. This study reports on a large number of patients with N0, N1mi, or N1 disease for 10 years, and reveals statistically significant prognostic information.CrossRefPubMedGoogle Scholar
- 18.NCCN Clinical Practice Guidelines in Clinical Oncology, Breast Cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed July 29, 2010.
- 19.American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer, September 12, 2005. Available at: http://www.asco.org/ASCOv2/Practice+%26+Guidelines/Guidelines/Clinical+Practice+Guidelines/Breast+Cancer Accessed July 29, 2010.
- 23.• Cox CE, Kiluk JV, Riker AI, et al.: Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg 2008, 206:261–268. This study reports a difference in DFS and OS for patients with micrometastatic disease. However, it failed to show a benefit for axillary dissection in micrometastatic disease.CrossRefPubMedGoogle Scholar
- 24.•• De Boer M, Van Deurzen CHM, Van Dijck JAAM, et al.: Micrometastasis or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009, 361:653–663. The DFS of patients with micrometastasis and isolated tumor cells based on adjuvant chemotherapy and the possible value of axillary dissection was discussed.CrossRefPubMedGoogle Scholar
- 25.Meretoja TJ, Vironen JH, Heikkila PS, Leidenius MH: Outcome of selected breast cancer patients with micrometastasis or isolated tumor cells in sentinel node biopsy and no completion axillary lymph node dissection. J Surg Oncol 2010, In press.Google Scholar
- 30.• Sakakibara M, Nagashima T, Kadowaki M, et al.: Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastasis. Ann Surg Oncol 2009, 16:2470–2478. This article reported a statistical difference for DFS and OS in N1 patients who received neoadjuvant chemotherapy.CrossRefPubMedGoogle Scholar
- 33.Bear HD, Anderson S, Brown A, et al.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003, 21:4165–4174.CrossRefPubMedGoogle Scholar
- 35.• Classe JM, Bordes V, Campion L, et al.: Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 2009, 27:726–732. This is a small prospective study evaluating the success of SNB after neoadjuvant chemotherapy in patients with N0 and N1 disease.CrossRefPubMedGoogle Scholar
- 36.• Ozmen V, Unal ES, Muslumanoglu ME, et al.: Axillary sentinel node biopsy after neoadjuvant chemotherapy. Eur J Surg Oncol 2010, 36:23–29. This study provides evidence on the usefulness of SNB and intraoperative cytopathology to confirmed nodal disease and its prognostic value in patients following neoadjuvant chemotherapy.PubMedGoogle Scholar
- 37.• Schwartz GF, Tannebaum JE, Jernigan AM, Palazzo JP: Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast. Cancer 2010, 116:1243–1251. This is a small retrospective study evaluating the authors’ experience with SNB after neoadjuvant chemotherapy.CrossRefPubMedGoogle Scholar